An interventional study of XVIVO heart preservation devices and Standard ICSS in Heart Transplantation, sponsored by XVIVO Perfusion. Active, not recruiting at 15 sites in 8 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-04-21.
Sponsored by XVIVO Perfusion · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The study intends to compare standard ischemic cold static storage (ICSS) of retrieved hearts intended to be transplanted, to non-ischemic heart preservation (NIHP) in a randomized clinical multicentre trial. The primary hypothesis is that the non-ischemic hypothermic cardioplegic preservation (NIHP) is safe and superior to ischemic cold static storage (ICSS) of donor hearts. The study will investigate the safety and superiority of the new methodology in terms of improved immediate and prolonged organ function in adult heart transplanted patients.
This study will investigate if non-ischemic heart preservation (NIHP) with the XVIVO heart preservation devices could improve clinical outcome of patients receiving hearts after use of the technology compared to after use of standard cold ischemic preservation. This will be investigated in a European multicentre randomized controlled clinical trial. For technical reasons, blinding to the involved clinical personnel is not possible, however, biopsies will be blinded to study pathologists. The trial will include 202 recipients that have been randomized through their heart donor. The primary outcome of the study is a clinically relevant composite including graft survival, primary graft dysfunction, rejection and use of circulatory mechanical support, within 30 days and also including Cardiac Allograft Vasculopathy within 12 months. As secondary outcomes, molecular markers related to cardiac injury CKMB, ProBNP and TNI will be investigated as well as markers of the inflammatory response. Safety aspects such as effect on other organs and machine defects will also be monitored. The study population is adults, listed for heart transplantation and donors accepted as heart donors according to standard hospital procedures. Specific recipient exclusion criteria related to pre-transplant ECMO support, patients undergoing pre-transplant desensitization protocol, patients with Grown-Up Congenital Heart Disease, patients with severe kidney or liver dysfunction, patients with septicaemia, and patients diagnosed with Systemic Lupus Erythematous, sarcoidosis or amyloidosis are excluded. Cardiac death donors and donors with previous sternotomy are excluded. The study hypothesis is that NIHP better preserves the endothelium and myocyte function of the heart resulting in improved short- and medium-term recipient outcome, without inducing any new significant risks to the retrieved heart or the recipient. This is believed to be accomplished through continuous oxygenation of the heart via perfusion of the coronary arteries using an optimized preservation solution, mimicking the normal environment for the endothelium.
XVIVO Perfusion is the lead sponsor of 10 studies on the registry; 3 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Inclusion Criteria recipient:
Inclusion criteria donor:
Exclusion Criteria recipient:
Exclusion criteria donor:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Continous cold cardioplegic perfusion of hearts
Device: XVIVO heart preservation devices
Standard preservation technique
Device: Standard ICSS
The intervention is to preserve hearts during transportation cold, cardioplegic and non-ischemic, with a high oncotic and hormone supplemented perfusate.
Cold static preservation using standard preservation solution
30 days mortality and 30 days graft dysfunction
The Primary End-Point is defined as time-to-first-event of cardiac related death, moderate or severe primary graft dysfunction of the left ventricle or primary graft dysfunction of the right ventricle (according to Kobashigawa et al., 2014), acute cellular rejection ≥2R (according to Stewart et al., 2005) or graft failure (use of mechanical circulatory support or retransplantation) within 30 days.
Time frame: 30 days
1 year mortality and 1 year graft dysfunction
The key secondary endpoint is defined as time-to-first-event of either any cause of death, moderate or severe PGD-LV or PGD-RV (according to Kobashigawa et al., 2014), acute cellular rejection ≥2R (according to Stewart et al., 2005) or graft failure (use of mechanical circulatory support or retransplantation) or CAV ≥ 1 (according to Mehra, 2010) within 12 months.
Time frame: 1 year
30 days and 1 year mortality and graft dysfunction
The individual variables included in the composite primary endpoint at 30 days and 1 year analyzed as time-to-first-event.
Time frame: 30 days and 1 year
CKMB
Creatine kinase MB (CKMB) at 6 ±2 h, 24 ±6 h, 48±6 h and 72±6 h after cross clamp removal
Time frame: 3 days
TnI
Tropinin I (TnI) at 6 ±2 h, 24 ±6 h, 48±6 h and 72±6 h after cross clamp removal
Time frame: 3 days
ProBNP
Pro Brain Natriuretic Protein (ProBNP) at 6 ±2 h, 24 ±6 h, 48±6 h and 72±6 h after cross clamp removal
Time frame: 3 days
Stay in ICU
Length of Stay at Intensive Care Unit, reported as number of days
Time frame: 1 year
Cardiac Transplant Events
Incidence of Major Adverse Cardiac Transplant Events
Time frame: 1 year
Postoperative use of mechanical circulatory support
Incidence of use of postoperative mechanical circulatory support, reported as number of days
Time frame: 1 year
Postoperative duration of mechanical circulatory support
Duration of use of postoperative mechanical circulatory support, reported as number of days
Time frame: 1 year
Overall success/failure 30 days
Success is defined as a recipient that are transplanted and alive at 30 days without any of the complication in the primary endpoint before 30 days.
Time frame: 30 days
Overall success/failure 1 year
Success is defined as a recipient that are transplanted and alive at 1 year without any of the complication given in key secondary endpoint before 1 year.
Time frame: 1 year
ECHO data (Left ventricular ejection fraction)
ECHO data with Left ventricular ejection fraction in percentage within 24 hours after transplantation
Time frame: 24 hours
ECHO data (Left ventricular ejection fraction)
ECHO data with Left ventricular ejection fraction in percentage 1 week after transplantation
Time frame: 1 week
ECHO data (Left ventricular ejection fraction)
ECHO data with Left ventricular ejection fraction in percentage 6 months after transplantation
Time frame: 6 months
ECHO data (Left ventricular ejection fraction)
ECHO data with Left ventricular ejection fraction in percentage 1 year after transplantation
Time frame: 1 year
ECHO data (Right ventricular ejection fraction)
ECHO data with Right ventricular ejection fraction in percentage within 24 hours after transplantation
Time frame: 24 hours
ECHO data (Right ventricular ejection fraction)
ECHO data with Right ventricular ejection fraction in percentage 1 week after transplantation
Time frame: 1 week
ECHO data (Right ventricular ejection fraction)
ECHO data with Right ventricular ejection fraction in percentage 6 months after transplantation
Time frame: 6 months
ECHO data (Right ventricular ejection fraction)
ECHO data with Right ventricular ejection fraction in percentage 1 year after transplantation
Time frame: 1 year
ECHO data (Tricuspid annular plane systolic excursion)
ECHO data with Tricuspid annular plane systolic excursion (TAPSE) in mm within 24 hours after transplantation
Time frame: 24 hours
ECHO data (Tricuspid annular plane systolic excursion)
ECHO data with Tricuspid annular plane systolic excursion (TAPSE) in mm 1 week after transplantation
Time frame: 1 week
ECHO data (Tricuspid annular plane systolic excursion)
ECHO data with Tricuspid annular plane systolic excursion (TAPSE) in mm 6 months after transplantation
Time frame: 6 months
ECHO data (Tricuspid annular plane systolic excursion)
ECHO data with Tricuspid annular plane systolic excursion (TAPSE) in mm 1 year after transplantation
Time frame: 1 year
Serious adverse device effects
Incidence of any serious adverse device effects.
Time frame: 1 year
Adverse device effects
Incidence of any adverse device effects
Time frame: 1 year
Device dysfunction resulting in loss of transplantable heart
Number of transplantable hearts lost due to device dysfunction
Time frame: 12 hours
Intra operative details; duration of ECC
Duration of ECC in minutes
Time frame: 12 hours
Intra operative details; duration of cross clamp
Duration of cross clamp in minutes
Time frame: 12 hours
Intra operative details; duration of surgery
Duration of surgery in minutes
Time frame: 12 hours
Intra operative details; attempts to wean off ECC
Number of attempts to wean off ECC
Time frame: 12 hours
Intra operative details; need for inotropic support
Need for inotropic support (inotropic score)
Time frame: 12 hours
Intra operative details; need for pulmonary vasodilator
Need for pulmonary vasodilator
Time frame: 12 hours
Intra operative details; defibrillations
Number of defibrillations
Time frame: 12 hours
Intra operative details; arryhythmias
Occurence of arryhythmias
Time frame: 12 hours
Intra operative details; conduction abnormalities
Number of conduction abnormalities
Time frame: 12 hours
Intra operative details; Left ventricular ejection fraction (LVEF)
LVEF in percentage
Time frame: 12 hours
Intra operative details; Right ventricular ejection fraction (RVEF)
RVEF in percentage
Time frame: 12 hours
Intra operative details; Mitral valve regurgitations
Grade of mitral valve regurgitations
Time frame: 12 hours
Intra operative details; Tricuspid valve regurgitations
Occurence of tricuspid vavle regurgitations
Time frame: 12 hours
Arterial blood gas lactate
Arterial blood gas lactate at 6 hours
Time frame: 6 hours
Arterial blood gas lactate
Arterial blood gas lactate at 24 hours
Time frame: 24 hours
Pro-BNP during follow up
Pro-BNP at predefined time points during follow-up.
Time frame: 1 year
Plan to share: No
Ran from Nov 2020 to primary completion in Aug 2023, 33 months.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
XVIVO Perfusion